Full-Time
Confirmed live in the last 24 hours
Produces synthetic DNA for biotechnology applications
No salary listed
Entry, Junior
Tualatin, OR, USA
Twist Bioscience focuses on DNA synthesis, creating synthetic DNA for use in biotechnology, pharmaceuticals, and research. Their proprietary platform allows for the rapid and accurate production of DNA sequences, providing clients with products like genes, oligo pools, and variant libraries. What sets Twist apart is their ability to handle complex DNA sequences and offer high-quality products at competitive prices. The company's goal is to support advancements in science and medicine by being a leading supplier in the DNA synthesis market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Twist Bioscience named a Best Idea for 2025 at TD Cowen.
Absci, a pioneer in generative AI-driven drug discovery, and Twist Bioscience, a leader in high-quality synthetic DNA production through its silicon platform, have announced an innovative collaboration to create a novel therapeutic antibody using generative AI.
In other recent news, Twist Bioscience has secured a $15 million capital boost from a new financial agreement with XOMA Royalty Corporation.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator.
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer.